First-line axitinib versus sorafenib in Asian patients with metastatic renal cell carcinoma: exploratory subgroup analyses of Phase III data

Efficacy/safety of first-line axitinib in Asian patients with metastatic renal cell carcinoma.

Patients were assigned (2:1) to 5-mg axitinib (n = 48) or 400-mg sorafenib (n = 24) twice daily. Primary end point was progression-free survival. Objective response rate, overall survival and adverse events were also assessed.

For axitinib versus sorafenib, hazard ratio for progression-free survival was 0.652 (95% CI: 0.340-1.252; p = 0.0989), objective response rate was higher (35.4 vs 16.7%; p = 0.0495), overall survival longer (hazard ratio: 0.739; 95% CI: 0.397-1.375; p = 0.1683). Palmar-plantar erythrodysesthesia (57.4%), diarrhea (55.3%), hypertension (51.1%) were commonest adverse events with axitinib; palmar-plantar erythrodysesthesia (50.0%) with sorafenib.

Axitinib improved efficacy in Asian patients with metastatic renal cell carcinoma; adverse events were consistent with previous findings.

Future oncology (London, England). 2018 Jul 30 [Epub ahead of print]

Xinan Sheng, Feng Bi, Xiubao Ren, Ying Cheng, Jinwan Wang, Brad Rosbrook, Ming Jiang, Jun Guo

Key Laboratory of Carcinogenesis & Translational Research (Ministry of Education/Beijing), Department of Renal Cancer & Melanoma, Peking University Cancer Hospital & Institute, Beijing, PR China., Department of Medical Oncology, West China Hospital of Sichuan University, Chengdu, Sichuan Province, PR China., Department of Biology Treatment, Tianjin Oncology Hospital, Tianjin, PR China., Department of Oncology, Jilin Provincial Cancer Hospital, Changchun, Jilin Province, PR China., Department of Medical Oncology, Cancer Hospital Chinese Academy of Medical Sciences, PR China., Pfizer Oncology, San Diego, CA, USA., Pfizer Oncology Medical Affairs, Shanghai, PR China.